Endocrine Abstracts

Introduction: New treatments of diabetes, such as dapagliflozin, improve global metabolic status beyond glycemic control.

Aim: To evaluate tolerance to dapagliflozin and its effects on metabolic control in type 2 diabetes and obese patients attended in endocrinology offices.

Material and method: A prospective study of patients with type 2 diabetes and obesity. In an intra-subject analysis, clinical and analytical data were evaluated at baseline and after dapagliflozin treatment.

Results: We studied 38 patients (47.4% women) with type 2 diabetes and obesity. Average age was 55.7±1.5 years, average duration of diabetes was 10.7±1.7 years and 40.9 and 91.3% had family history of cardiovascular disease and diabetes, respectively. At baseline, 78.9% of the patients had metformin, 39.5% others oral hypoglycemic agents, 13.2% glp-1 agonists and 44.7% insulin. We re-evaluated the patients 3.9±0.2 months after treatment with dapagliflozin. We found significant improvements in weight (P<0.001), bmi (P<0.001), sbp (P=0.008), dbp (P=0.030), fasting glucose (P=0.001), hba1c (P<0.001), total-chol (P=0.011), ldl-chol (P=0.038) tg (P=0.025), gpt (P=0.032), and lipids drugs (P<0.001). No changes in levels of creatinine and glomerular filtration rate were observed. Regarding tolerance to dapagliflozin, only 7.9% developed urinary tract infections.

Conclusions: Significant improvement of anthropometric parameters and glycemic control in terms of fasting glucose and hba1c, and significant improvements of blood pressure, gpt and lipid profile were observed. Only 7.9% developed urinary tract infections. In addition, we found a significant intensification of lipid-lowering therapy.